SecSonar.com

Lipocine Inc. (LPCN)

Lipocine Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Lipocine Inc. (LPCN) is a Biotechnology company based in US with a market capitalization of $13.2M. Revenue declined 82.3% year-over-year and free cash flow was negative at -$9.8M. This page tracks LPCN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 16 employees · IPO Oct 22, 2013

Valuation

Valuation & price

$2.26 · as of May 17, 2026 · -79.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.91

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$11.26$6.60$1.94Jul 25Dec 25Jun 26Jul 7, 25$3.11Jul 9, 25$3.21Jul 11, 25$3.27Jul 15, 25$3.00Jul 17, 25$3.17Jul 21, 25$3.17Jul 23, 25$3.27Jul 25, 25$3.44Jul 29, 25$3.27Jul 31, 25$3.23Aug 4, 25$3.13Aug 6, 25$3.02Aug 8, 25$2.93Aug 12, 25$2.97Aug 14, 25$3.04Aug 19, 25$2.96Aug 21, 25$3.01Aug 25, 25$3.02Aug 27, 25$3.01Aug 29, 25$2.91Sep 3, 25$2.90Sep 5, 25$2.89Sep 9, 25$2.87Sep 11, 25$2.94Sep 15, 25$2.97Sep 17, 25$2.85Sep 19, 25$2.88Sep 23, 25$2.76Sep 25, 25$2.68Sep 29, 25$2.81Oct 2, 25$3.09Oct 6, 25$3.20Oct 8, 25$3.16Oct 10, 25$3.10Oct 14, 25$3.21Oct 16, 25$3.11Oct 20, 25$2.92Oct 22, 25$2.81Oct 24, 25$2.90Oct 28, 25$2.75Oct 30, 25$2.60Nov 3, 25$2.65Nov 5, 25$2.56Nov 7, 25$2.54Nov 11, 25$2.89Nov 14, 25$2.87Nov 18, 25$3.38Nov 20, 25$3.15Nov 24, 25$3.25Nov 26, 25$3.28Dec 1, 25$3.31Dec 3, 25$3.09Dec 5, 25$3.15Dec 9, 25$3.27Dec 11, 25$3.18Dec 15, 25$3.15Dec 17, 25$3.67Dec 19, 25$4.25Dec 23, 25$4.61Dec 26, 25$5.23Dec 31, 25$8.03Jan 5, 26$7.30Jan 7, 26$7.52Jan 9, 26$8.01Jan 13, 26$10.47Jan 15, 26$11.26Jan 20, 26$9.92Jan 22, 26$10.45Jan 26, 26$10.71Jan 28, 26$9.46Jan 30, 26$9.00Feb 3, 26$8.35Feb 5, 26$7.72Feb 9, 26$8.89Feb 11, 26$8.72Feb 17, 26$9.45Feb 19, 26$9.37Feb 23, 26$9.50Feb 25, 26$9.48Feb 27, 26$9.96Mar 3, 26$8.42Mar 5, 26$8.19Mar 9, 26$7.88Mar 11, 26$8.99Mar 13, 26$7.34Mar 17, 26$7.67Mar 19, 26$7.31Mar 23, 26$7.31Mar 25, 26$7.43Mar 27, 26$7.15Apr 1, 26$9.25Apr 6, 26$1.94Apr 8, 26$2.13Apr 10, 26$2.20Apr 14, 26$2.53Apr 16, 26$2.56Apr 20, 26$2.30Apr 22, 26$2.42Apr 24, 26$2.42Apr 28, 26$2.31Apr 30, 26$2.33May 4, 26$2.29May 6, 26$2.43May 8, 26$2.37May 12, 26$2.33May 15, 26$2.26May 19, 26$2.20May 21, 26$2.22May 26, 26$2.26May 28, 26$2.26Jun 1, 26$2.28Jun 3, 26$2.19Jun 5, 26$2.05Jun 9, 26$2.05Jun 11, 26$2.20Jun 15, 26$2.29Jun 17, 26$2.34Jun 22, 26$2.29Jun 24, 26$2.47Jun 30, 26$2.45
$1.9452-week range$11.26
Loading valuation history…

Fundamentals

Key fundamentals

$13.2M

Market cap

-82.3%

Revenue growth (YoY)

-334.3%

Gross margin

-$9.8M

Free cash flow (USD)

-$14.9M

Net debt

Net cash position

2.1%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$428.0KFY 2019$165.0KFY 2020$0.00FY 2021$16.1MFY 2022$500.0KFY 2023$-2.9MFY 2024$11.2MFY 2025$2.0M
$0$2M

Free cash flow by year

2016 → 2025

FY 2016$-18.3MFY 2017$-16.7MFY 2018$-12.1MFY 2019$-11.7MFY 2020$-15.3MFY 2021$-4.4MFY 2022$-12.1MFY 2023$-11.9MFY 2024$-1.3MFY 2025$-9.8M
-$18.3M-$9.8M

Gross margin by year

2021 → 2025

FY 202152.5%FY 2022-1611.4%FY 2023456.9%FY 2024100.0%FY 2025-334.3%
52.5%-334.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

3

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventKOL Event HostedJun 12, 2026Filing
  • 8-K eventVirtual KOL Event AnnouncementJun 4, 2026Filing
  • 8-K eventStock Incentive Plan UpdateJun 4, 2026Filing
  • 8-K eventClinical Data PresentationMay 26, 2026Filing
  • 8-K eventPhase 3 Data PresentationMay 19, 2026Filing
  • 8-K eventPresentation AnnouncementMay 18, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • 8-K eventCorporate Presentation UpdateMay 7, 2026Filing
  • 8-K eventDirector ResignationApr 21, 2026Filing

Questions

Frequently asked questions

What is Lipocine Inc.'s market cap?

Lipocine Inc. (LPCN) has a market capitalization of $13.2M.

What is LPCN's P/E ratio?

A meaningful P/E ratio is not available for LPCN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is LPCN's price-to-book (P/B) ratio?

LPCN trades at 0.91 times book value per share.

Are insiders buying LPCN stock?

Yes — SEC Form 4 filings show 3 open-market insider buys and 0 sells at Lipocine Inc. in the last 90 days.

Same arena

Related companies in Biotechnology

GDTC

CytoMed Therapeutics Limited

$13.4M

TRAW

Traws Pharma, Inc.

$13.4M

HIND

Vyome Holdings, Inc.

$13M

CYCN

Cyclerion Therapeutics, Inc.

$13.6M

TAOX

TAO Synergies Inc.

$14M

LEXX

Lexaria Bioscience Corp.

$12.2M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.